A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity.
about
Grand challenges in cellular biochemistry: the "next-gen" biochemistryA phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumoursPhase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.Targeting hypoxia in the leukemia microenvironmentAKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemiaInitial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.Application of population pharmacokinetics for preclinical safety and efficacy studies.Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.
P2860
Q28385256-32525051-06DD-4862-AA93-D7D079F63521Q33397528-0D10EBA7-15D9-480E-B631-932AE27F8C56Q33404024-8740805F-5619-4A8B-A5A7-FD5A5C59A690Q33420436-63600DEE-C81B-4E51-B05C-4EEA6FF84315Q34401785-D54E7426-0211-4189-AFB2-736D3DD9FBFAQ34482552-BE375859-6319-4E39-897B-92578FC91406Q35005290-9E149302-AF8D-4C35-8C51-C213FB3E4E54Q36212847-87CEE8D8-D8B4-40C1-9C2C-EF687B4BEDDBQ37217739-76D0BFA4-368E-4F89-BDC4-0F060D7BDBD4Q38128345-1C8AA2FE-9AD5-4837-BAE7-26959AAA7B17Q38177279-1B3EE047-FA3B-498E-A6F9-A7E2DD0765CC
P2860
A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
A combined pharmacokinetic mod ...... ces in clearance and toxicity.
@en
A combined pharmacokinetic mod ...... ces in clearance and toxicity.
@nl
type
label
A combined pharmacokinetic mod ...... ces in clearance and toxicity.
@en
A combined pharmacokinetic mod ...... ces in clearance and toxicity.
@nl
prefLabel
A combined pharmacokinetic mod ...... ces in clearance and toxicity.
@en
A combined pharmacokinetic mod ...... ces in clearance and toxicity.
@nl
P2093
P2860
P1476
A combined pharmacokinetic mod ...... nces in clearance and toxicity
@en
P2093
Kashyap Patel
Kevin O Hicks
Steve S F Choy
Teresa J Melink
William R Wilson
P2860
P2888
P304
P356
10.1007/S00280-010-1412-Z
P50
P577
2010-08-04T00:00:00Z